RadioMedix, Inc. is a clinical-stage biotechnology company focused on innovative radiopharmaceuticals for diagnosis, monitoring, and (TAT) of cancer.
RadioMedix, Inc. is a clinical-stage biotechnology company, focused on innovative radiopharmaceuticals for diagnosis, monitoring, and Targeted Alpha Therapy (TAT) of cancer. The company has also established facilities including a drug discovery center for the early probe development, a pre-clinical core facility for in vitro and in vivo evaluation of radiopharmaceuticals, and 27,500 SQF cGMP manufacturing and analytical suite for Phase I-III clinical trials, and the large-scale post-approval commercial manufacturing, also known as “The Spica Center”. RadioMedix received FDA approval for it’s first PET diagnostic radiopharmaceutical , Cu-64-DOTATATE (Detectnet™ ) in September of 2020. RadioMedix is developing a platform of TAT radiopharmaceuticals using Pb-212 and Ac-225 for unmet needs in oncology such as brain tumors, pancreatic cancer and prostate cancer. RadioMedix’s lead TAT compound is Pb-212 -DOTAMTATE. This drug is completing phase II trial with exemplary results in patients with somatostatin expressing neuroendocrine cancers. To learn more, visit www.radiomedix.com.